Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
Public ClinicalTrials.gov record NCT05600114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study, Evaluating the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution in Subjects With Social Anxiety Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).
Study identification
- NCT ID
- NCT05600114
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 239 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2022 (Actual)
- Primary completion
- Dec 13, 2023 (Actual)
- Completion
- Dec 13, 2023 (Actual)
- Last update posted
- Nov 21, 2024
2022 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 8
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| EPI-CBD-001 Site | Encino | California | 91316 | — |
| EPI-CBD-001 Site | Lemon Grove | California | 91945 | — |
| EPI-CBD-001 Site | Los Alamitos | California | 90720 | — |
| EPI-CBD-001-Site | Oceanside | California | 92056 | — |
| EPI-CBD-001 site | San Jose | California | 95124 | — |
| EPI-CBD-001 Site | Jacksonville | Florida | 32256 | — |
| EPI-CBD-001 Site | Lauderhill | Florida | 33319 | — |
| EPI-CBD-001 Site | Maitland | Florida | 32751 | — |
| EPI-CBD-001 Site | Orlando | Florida | 32801 | — |
| EPI-CBD-001 Site | Chicago | Illinois | 60640 | — |
| EPI-CBD-001 Site | Cedarhurst | New York | 11516 | — |
| EPI-CBD-001-Site | New York | New York | 10036 | — |
| EPI-CBD-001-Site | Rochester | New York | 10036 | — |
| EPI-CBD-001 Site | Oklahoma City | Oklahoma | 73106 | — |
| EPI-CBD-001 Site | Portland | Oregon | 97210 | — |
| EPI-CBD-001 site | Wichita Falls | Texas | 76309 | — |
| EPI-CBD-001 Site | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05600114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2024 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05600114 live on ClinicalTrials.gov.